2024
Pulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans
Parida S, MacLean R, Gueorguieva R, Sofuoglu M. Pulsed nicotine infusions as a model for smoking: validating a tool to explore nicotine thresholds in humans. Psychopharmacology 2024, 241: 1915-1922. PMID: 38970644, DOI: 10.1007/s00213-024-06609-6.Peer-Reviewed Original ResearchDiscriminative stimulus effectsAddiction thresholdNicotine doseDiscriminative stimulus effects of nicotineStimulus effects of nicotineNicotine deliveryEffects of nicotineOvernight abstinenceStimulus effectsNicotine infusionSubjective effectsTest sessionsNicotineMethodsEleven participantsInfusion procedureLow dosesParticipantsThreshold doseConclusionsTheseAbstinenceDoseHeart rateInfusionSmokingObjectivesToOvervaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder
Grilo C, Ivezaj V, Gueorguieva R. Overvaluation of shape/weight at posttreatment predicts relapse at 12‐month follow‐up after successful behaviorally‐based treatment of binge‐eating disorder. International Journal Of Eating Disorders 2024, 57: 1268-1273. PMID: 38321617, PMCID: PMC11093697, DOI: 10.1002/eat.24141.Peer-Reviewed Original ResearchOvervaluation of shape/weightEating-disorder psychopathologyBinge-eating disorderEating Disorder Examination interviewBeck Depression InventoryWeight loss treatmentClinical overvaluationBinge-eating frequencyDiagnostic specifierBinge eatingNon-abstinenceExamination interviewDepression InventoryShape/weightDepression scoresFollow-upPsychopathologyAbstinenceBingeDepressionClinical implicationsDepression 1PosttreatmentDisordersOvervaluation
2021
Randomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery
Grilo CM, Ivezaj V, Duffy AJ, Gueorguieva R. Randomized Controlled Trial of Treatments for Loss‐of‐Control Eating Following Bariatric Surgery. Obesity 2021, 29: 689-697. PMID: 33694287, PMCID: PMC7995173, DOI: 10.1002/oby.23124.Peer-Reviewed Original ResearchConceptsBariatric surgeryWeight lossAllied health cliniciansBariatric surgery outcomesThree-month treatmentSelf-help treatmentBariatric surgery settingsSignificant differencesControlled TrialsSurgery settingSurgery outcomesTreatment outcomesHealth cliniciansPosttreatment outcomesNon-White participantsControl eatingSurgeryTrialsOutcomesTreatmentPatientsCategorical outcomesWhite participantsAbstinenceHigher proportion
2017
Bayesian Joint Modelling of Longitudinal Data on Abstinence, Frequency and Intensity of Drinking in Alcoholism Trials
Buta E, O’Malley S, Gueorguieva R. Bayesian Joint Modelling of Longitudinal Data on Abstinence, Frequency and Intensity of Drinking in Alcoholism Trials. Journal Of The Royal Statistical Society Series A (Statistics In Society) 2017, 181: 869-888. PMID: 31123390, PMCID: PMC6527419, DOI: 10.1111/rssa.12334.Peer-Reviewed Original ResearchBayesian joint modellingParameter estimate biasStandard frequentist approachRandom effectsLog-normal modelJoint modelFrequentist approachBayesian approachMean squared errorJoint modellingEstimate biasIntensity of drinkingSimulation studyFrequency of drinkingSeparate modellingModellingLongitudinal outcomesClinical trialsSame subjectsSustained abstinenceModelLogistic partAbstinence
2015
An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate
Gueorguieva R, Wu R, Tsai WM, O’Connor P, Fucito L, Zhang H, O’Malley S. An analysis of moderators in the COMBINE study: Identifying subgroups of patients who benefit from acamprosate. European Neuropsychopharmacology 2015, 25: 1586-1599. PMID: 26141511, PMCID: PMC4600651, DOI: 10.1016/j.euroneuro.2015.06.006.Peer-Reviewed Original ResearchConceptsAcamprosate effectHeavy drinkingShort abstinenceEnhanced treatment responseMonths of treatmentSubgroup of patientsBody mass indexDrug plasma levelsIdentification of subgroupsBetter prognosisLower BMIMass indexPlasma levelsGlutamatergic hyperactivityTreatment responseAcamprosateCOMBINE StudyPrior treatmentLarger studyConsecutive daysAbstinencePretreatment abstinenceTreatment effectsCognitive inefficiencySubgroups
2014
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2014, 23: 288-293. PMID: 24724887, PMCID: PMC4600600, DOI: 10.1111/j.1521-0391.2014.12102.x.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DeterrentsAlcoholismDiagnosis, Dual (Psychiatry)DisulfiramDopamine beta-HydroxylaseDrug Therapy, CombinationFemaleGenotypeHeterozygoteHumansMaleMental DisordersMiddle AgedNaltrexoneNarcotic AntagonistsPolymorphism, Single NucleotideReceptors, Opioid, muTreatment OutcomeVeteransWhite PeopleConceptsAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsOPRM1 rs1799971Favorable responseMore abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking
2013
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias A, Gelernter J, Gueorguieva R, Ralevski E, Petrakis I. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2013 DOI: 10.1111/j.1521-0391.2013.12102.x.Peer-Reviewed Original ResearchAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsFavorable responseOPRM1 rs1799971More abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking